LENZ (STOCKS)
LENZ Therapeutics, Inc. Common Stock
$9.630000
+0.560000 (+6.17%)
Prev close: $9.070000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Evert B. Schimmelpennink
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $301.94M
- Employees
- 42
- P/E (TTM)
- -3.44
- P/B (TTM)
- 1.00
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
6
Strong Buy
6
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-1.16 | $-0.99 | -0.1694 | -17.10% |
|
Sep 2025 (Q3)
|
$-0.59 | $-0.72 | +0.1304 | +18.10% |
|
Jun 2025 (Q2)
|
$-0.51 | $-0.62 | +0.1123 | +18.05% |
|
Mar 2025 (Q1)
|
$-0.53 | $-0.56 | +0.0344 | +6.10% |
Financial Statements
| Revenues | $19.09M |
| Benefits Costs and Expenses | $100.71M |
| Cost Of Revenue | $418.00K |
| Costs And Expenses | $110.23M |
| Gross Profit | $18.67M |
| Nonoperating Income/Loss | $9.51M |
| Operating Expenses | $109.81M |
| Selling, General, and Administrative Expenses | $91.14M |
| Research and Development | $18.67M |
| Operating Income/Loss | -$91.14M |
| Income/Loss From Continuing Operations After Tax | -$82.13M |
| Income/Loss From Continuing Operations Before Tax | -$81.63M |
| Income Tax Expense/Benefit | $502.00K |
| Income Tax Expense/Benefit, Current | $502.00K |
| Income Tax Expense/Benefit, Deferred | $0.00 |
| Net Income/Loss | -$82.13M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$82.13M |
| Net Income/Loss Available To Common Stockholders, Basic | -$82.13M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$2.85 |
| Diluted Earnings Per Share | -$2.85 |
| Basic Average Shares | 28,813,164 |
| Diluted Average Shares | 28,813,164 |
| Assets | $305.88M |
| Current Assets | $301.41M |
| Cash | $292.30M |
| Inventory | $2.94M |
| Other Current Assets | $6.18M |
| Noncurrent Assets | $4.46M |
| Fixed Assets | $1.19M |
| Other Non-current Assets | $3.28M |
| Liabilities | $21.54M |
| Current Liabilities | $21.19M |
| Accounts Payable | $4.17M |
| Wages | $7.02M |
| Other Current Liabilities | $10.00M |
| Noncurrent Liabilities | $350.00K |
| Equity | $284.34M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $284.34M |
| Liabilities And Equity | $305.88M |
| Net Cash Flow From Operating Activities | -$69.17M |
| Net Cash Flow From Operating Activities, Continuing | -$69.17M |
| Net Cash Flow From Investing Activities | -$75.67M |
| Net Cash Flow From Investing Activities, Continuing | -$75.67M |
| Net Cash Flow From Financing Activities | $149.75M |
| Net Cash Flow From Financing Activities, Continuing | $149.75M |
| Net Cash Flow | $4.91M |
| Net Cash Flow, Continuing | $4.91M |
| Comprehensive Income/Loss | -$82.08M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$82.08M |
| Other Comprehensive Income/Loss | -$82.08M |